Traws Pharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Traws Pharma, Inc. (TRAW) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$215.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-14
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$215.00K.
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $159.00K.
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $89.00K.
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $3.00K.
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$26.57M.
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2018 was -$18.00K, a 101.22% decline from fiscal 2017.
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was $1.47M.
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2016 was -$3.99M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$215.00K 10-Q · filed 2026-08-14 | -$56.00K derived: sum of 2 quarters · filed 2026-08-14 | $33.00K derived: sum of 3 quarters · filed 2026-08-14 | $36.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $159.00K 10-Q · filed 2026-08-14 | $248.00K derived: sum of 2 quarters · filed 2026-08-14 | $251.00K derived: sum of 3 quarters · filed 2026-08-14 | $105.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $89.00K derived: 10-K 12 month − 3 quarters · filed 2026-04-15 | $92.00K derived: sum of 2 quarters · filed 2026-04-15 | -$54.00K derived: sum of 3 quarters · filed 2026-04-15 | -$26.57M 10-K · filed 2026-04-15 | |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-13 | -$143.00K derived: sum of 2 quarters · filed 2025-11-13 | -$26.66M derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2025-06-30 | -$146.00K 10-Q · filed 2025-11-13 | -$26.66M derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2025-03-31 | -$26.51M 10-Q · filed 2025-11-13 | ||||
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 3 quarters · filed 2019-04-01 | -$1.00K derived: sum of 2 quarters · filed 2019-04-01 | -$4.00K derived: sum of 3 quarters · filed 2019-04-01 | -$18.00K 10-K · filed 2019-04-01 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-14 | -$3.00K derived: sum of 2 quarters · filed 2018-11-14 | -$17.00K derived: sum of 3 quarters · filed 2018-11-14 | $1.47M derived: sum of 4 quarters · filed 2019-04-01 | |
| 2018-06-30 | -$3.00K 10-Q · filed 2018-11-14 | -$3.00K 10-Q · filed 2018-08-14 | $1.47M derived: sum of 3 quarters · filed 2019-04-01 | $1.51M derived: sum of 4 quarters · filed 2019-04-01 | |
| 2018-03-31 | -$14.00K 10-Q · filed 2018-11-14 | $14.00K 10-Q · filed 2018-05-15 | $1.47M derived: sum of 2 quarters · filed 2019-04-01 | $1.51M derived: sum of 3 quarters · filed 2019-04-01 | $1.46M derived: sum of 4 quarters · filed 2019-04-01 |
| 2017-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.53M derived: sum of 2 quarters · filed 2019-04-01 | $1.47M derived: sum of 3 quarters · filed 2019-04-01 | $1.47M 10-K · filed 2019-04-01 | |
| 2017-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$13.00K derived: sum of 2 quarters · filed 2017-11-09 | -$13.00K 10-Q · filed 2017-11-09 | $533.00K derived: sum of 4 quarters · filed 2018-03-16 | |
| 2017-06-30 | -$53.00K 10-Q · filed 2017-11-09 | -$53.00K 10-Q · filed 2017-08-14 | $493.00K derived: sum of 3 quarters · filed 2018-03-16 | -$2.21M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2017-03-31 | $1.55M 10-Q · filed 2017-11-09 | $546.00K derived: sum of 2 quarters · filed 2018-03-16 | -$2.16M derived: sum of 3 quarters · filed 2018-03-16 | -$2.17M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2016-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$3.71M derived: sum of 2 quarters · filed 2018-03-16 | -$3.72M derived: sum of 3 quarters · filed 2018-03-16 | -$3.99M 10-K · filed 2018-03-16 | |
| 2016-09-30 | -$2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$2.71M derived: sum of 2 quarters · filed 2016-11-14 | -$2.98M 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$279.00K 10-Q · filed 2016-08-15 | |||
| 2016-03-31 | -$271.00K 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |